Clinical trials: Lymphomas,
Acute Lymphoblastic Leukemia(ALL)
C-CAR011 Treatment in Subjects With ALL After HSCT
This is a single-center, prospective clinical study evaluating safety and efficacy of C-CAR011 treatment in subjects with ALL after HSCT
- Trial name
- NCT03327285
- Testing
- C-CAR011
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Leukemia
Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects of dasatinib in treating patients with chronic myelogenous…
- Trial name
- NCT00345826
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Relapsed or Refractory Peripheral T-cell Lymphoma
Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma
A non-interventional, multicenter, multinational retrospective analysis using electronic case report forms completed by the investigators based on information from patient medical records
- Trial name
- NCT03356678
- Testing
- Pralatrexate
- Where
- 2 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Hodgkin Lymphoma
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma
The goal of this clinical trial is to test the effect of tislelizumab treatment in patients with Hodgkin lymphoma. The main question it aims to answer is whether including a drug called tislelizumab in first-line treatment of…
- Trial name
- RATiFY (NCT05627115)
- Testing
- Tislelizumab, AVD, Radiotherapy
- Volunteers
- 80 people
- Sponsor
- University College, London
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy…
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT05633615
- Testing
- Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography
- Where
- 95 sites in United States
- Volunteers
- 396 people
- Sponsor
- SWOG Cancer Research Network
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
In-Vivo Activated T-Cell Depletion to Prevent GVHD
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00594308
- Testing
- Cyclophosphamide, Fludarabine, Cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma
- Trial name
- NCT00019708
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL)
Safety and Efficacy Evaluation of CD19-UCART
The purpose of this study is to evaluate the safety and efficacy of ascending doses of CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
- Trial name
- NCT03229876
- Testing
- CD19-UCART
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Bioray Laboratories
Lymphoma, Non-Hodgkin's Lymphoma
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
- Conditions
- Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- NCT01149668
- Testing
- PCI-24781
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Pharmacyclics LLC.
Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of SGN-30 when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with recurrent anaplastic large…
- Trial name
- NCT00354107
- Testing
- monoclonal antibody SGN-30, therapeutic hydrocortisone, ifosfamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Follicular
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
The purpose of this study is to assess the feasibility, efficacy and safety of adding bevacizumab to rituximab compared to rituximab alone in patients with previously treated follicular non-hodgkin's lymphoma (NHL) whose disease…
- Trial name
- NCT00193492
- Testing
- Bevacizumab, Rituximab
- Where
- 22 sites in United States
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV…
- Trial name
- SIGMA (NCT07582432)
- Testing
- Gamunex-C, 10% Injectable Solution
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Grifols Biologicals, LLC
Advanced Solid Tumors, Lymphomas
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
The purpose of this study was to determine the metabolism and elimination of 14C-lenvatinib in participants with advanced solid tumors or lymphomas, who were unsuitable for, or had failed, existing therapies.
- Trial name
- NCT02578316
- Testing
- Lenvatinib
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Eisai Inc.
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells
The goal of this clinical research study is to learn if an infusion of white blood cells (called T cells) that have been genetically changed is safe to give patients who have received an umbilical cord blood transplant (UCBT).
- Trial name
- NCT01362452
- Testing
- T-Cell Infusion, Cord Blood Infusion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of…
- Conditions
- Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL), Primary Mediastinal Large B-Cell Lymphoma-Refractory
- Trial name
- CD20/19 CAR T (NCT06703892)
- Testing
- GF-CART01
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
Relapsed Non-Hodgkin-Lymphoma
Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma
The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy in patients with relapsed/refractory aggressive and…
- Trial name
- Mz-135 (NCT02099292)
- Testing
- Rituximab and DexaBEAM
- Volunteers
- 103 people
- Sponsor
- Georg Hess, MD
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
This phase I multicenter feasibility trial is studying the safety and potential efficacy of infusing ex vivo expanded cord blood progenitors with one unmanipulated umbilical cord blood unit for transplantation following…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00343798
- Testing
- cyclophosphamide, fludarabine phosphate, cyclosporine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fred Hutchinson Cancer Center
T-cell Acute Lymphoblastic Leukemia
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
- Trial name
- NCT05289687
- Testing
- Daratumumab / Hyaluronidase Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eastern Cooperative Oncology Group
Refractory or Relapsed Non-Hodgkin's Lymphoma
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
This is an interventionnal pilot study to investigate whether 18FDG radiomics or serum metabolomic signatures could be predictive or prognostic factors in the follow-up of patients receiving CAR T-cell therapy for refractory…
- Trial name
- CART-Omic (NCT05422521)
- Testing
- blood samples and 18FDG PET-CT exams
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.